A Study to Evaluate the Cue COVID Rapid Test

Overview

About this study

The purpose of this study is to to evaluate the analytical performance of the Cue Health rapid (25 minute) molecular test for SARS-CoV-2 RNA using the proprietary nasal sample wand, disposable cartridge, and reader being developed by Cue Health Inc.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Test:

  • Adult patients, 18 years or older.
  • Current order for SARS-CoV-2 testing to be collected at one of two participating collection sites in SW or SE MN.
  • Provide verbal consent for an additional nasal swab collection (15 seconds each nostril) for research use only.

Exclusion Test:

  • Children (patients under age 18).
  • Patients who do not give verbal consent for collection of additional nasal swab specimen.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Bradley Karon, M.D., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.

Mayo Clinic Footer